A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) (clinicaltrials.gov) - Apr 18, 2026 - P1 | N=50 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited | Trial primary completion date: Jun 2025 ➔ Jan 2027
First-in-human • Trial primary completion date • Oncology • Solid Tumor
|